Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level

References

• Samsu N, Bellini MI. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021;2021:1497449. doi:10.1155/2021/1497449
   PubMed Web of Science ®Google Scholar
• Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Methods Mol Biol. 2020;2067:3–7.
   PubMedGoogle Scholar
• Zhao L, Zou Y, Liu F. Transforming growth factor-beta 1 in diabetic kidney disease. Front Cell Dev Biol. 2020;8:187. doi:10.3389/fcell.2020.00187
   PubMed Web of Science ®Google Scholar
• Widiasta A, Wahyudi K, Sribudiani Y, et al. Thelevel of transforming growth factor-β as a possible predictor of cyclophosphamide response in children with steroid-resistant nephrotic syndrome. Biomedicine. 2021;11(3):68–75. doi:10.37796/2211-8039.1205
   PubMedGoogle Scholar
• Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–617. doi:10.1016/S2213-8587(19)30180-9
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743–754. doi:10.1016/S2213-8587(21)00242-4
   PubMed Web of Science ®Google Scholar
• Das SK, Roy DK, Chowdhury AA, et al. Correlation of eGFR By MDRD and CKD-EPI formula with creatinine clearance estimation in CKD patients and healthy subjects. Mymensingh Med J. 2021;30(1):35–42.
   PubMedGoogle Scholar
• Nagib AM, Elsayed Matter Y, Ashry Gheith O, et al. Diabetic nephropathy following posttransplant diabetes mellitus. Exp Clin Transplant. 2019;17(2):138–146. doi:10.6002/ect.2018.0157
   PubMed Web of Science ®Google Scholar
• Koch EAT, Nakhoul R, Nakhoul F, et al. Autophagy in diabetic nephropathy: a review. Int Urol Nephrol. 2020;52(9):1705–1712. doi:10.1007/s11255-020-02545-4
   PubMed Web of Science ®Google Scholar
• Tung CW, Hsu Y-C, Shih Y-H, et al. Glomerular mesangial cell and podocyte injuries in diabetic nephropathy. Nephrology. 2018;23(Suppl 4):32–37. doi:10.1111/nep.13451
   PubMed Web of Science ®Google Scholar
• Bonner R, Albajrami O, Hudspeth J, et al. Diabetic Kidney Disease. Prim Care. 2020;47(4):645–659. doi:10.1016/j.pop.2020.08.004
   PubMed Web of Science ®Google Scholar
• Zhang L, Miao R, Yu T, et al. Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: a systematic review and network meta-analysis. Pharmacol Res. 2022;177:106111. doi:10.1016/j.phrs.2022.106111
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases. Enalapril, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
   Google Scholar
• Fu EL, Clase CM, Evans M, et al. Comparative effectiveness of renin-angiotensin system inhibitors and calcium channel blockers in individuals with advanced CKD: a nationwide observational cohort study. Am J Kidney Dis. 2021;77(5):719–729.e1. doi:10.1053/j.ajkd.2020.10.006
   PubMed Web of Science ®Google Scholar
• Yamada T, Wakabayashi M, Bhalla A, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20(1):14. doi:10.1186/s12933-020-01197-z
   PubMed Web of Science ®Google Scholar
• Moon JS, Hong JH, Jung YJ, et al. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2022;33(6):424–442. doi:10.1016/j.tem.2022.03.005
   PubMed Web of Science ®Google Scholar
• Jongs N, Greene T, Chertow GM, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755–1766. doi:10.1016/S2213-8587(21)00243-6
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Wheeler DC, Stefánsson BV, et al. Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail. 2021;9(11):807–820. doi:10.1016/j.jchf.2021.06.017
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;883(15):1436–1446. doi:10.1056/NEJMoa2024816
   Google Scholar
• Jongs N, Chertow GM, Greene T, et al. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. J Am Soc Nephrol. 2022;33(11):2094–2107. doi:10.1681/ASN.2022030306
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Chertow GM, et al. Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020;35(2):274–282. doi:10.1093/ndt/gfz290
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Brosius FC, Cavender MA, et al. SGLT2 Inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis. 2021;77(1):94–109. doi:10.1053/j.ajkd.2020.08.003
   PubMed Web of Science ®Google Scholar